1.
|
Lee WM: Hepatitis B virus infection. N
Engl J Med. 337:1733–1745. 1997. View Article : Google Scholar : PubMed/NCBI
|
2.
|
Wong VW and Chan HL: Severe acute
exacerbation of chronic hepatitis B: a unique presentation of a
common disease. J Gastroenterol Hepatol. 24:1179–1186. 2009.
View Article : Google Scholar : PubMed/NCBI
|
3.
|
Liaw YF, Leung N, Kao JH, et al Chronic
Hepatitis B Guideline Working Party of the Asian-Pacific
Association for the study of the Liver: Asian-Pacific consensus
statement on the management of chronic hepatitis B: a 2008 update.
Hepatol Int. 2:263–283. 2008. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Liaw YF, Sung JJ, Chow WC, et al Cirrhosis
Asian Lamivudine Multicentre Study Group: Lamivudine for patients
with chronic hepatitic B and advanced liver disease. N Engl J Med.
351:1521–1531. 2004. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Chan HL, Wong VW, Hui AY, et al: Long-term
lamivudine treatment is associated with a good maintained response
in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
Antivir Ther. 11:465–471. 2006.PubMed/NCBI
|
6.
|
Wong VW, Wong GL, Tsang SW, et al:
Long-term follow-up of lamivudine treatment in patients with severe
acute exacerbation of hepatitis B e antigen (HBeAg)-positive
chronic hepatitis B. Antivir Ther. 13:571–579. 2008.PubMed/NCBI
|
7.
|
Tsubota A, Arase Y, Suzuki Y, et al:
Benefit of lamivudine therapy and factors associated with clinical
outcome in spontaneous severe acute exacerbation of chronic
hepatitis B virus infection. Intervirology. 47:335–341. 2004.
View Article : Google Scholar
|
8.
|
Ghany MG and Doo EC: Antiviral resistance
and hepatitis B therapy. Hepatology. 49(Suppl 5): S174–S184. 2009.
View Article : Google Scholar : PubMed/NCBI
|
9.
|
Tenney DJ, Rose RE, Baldick CJ, et al:
Long-term monitoring shows hepatitis B virus resistance to
entecavir in nucleoside-naïve patients is rare through 5 years of
therapy. Hepatology. 49:1503–1514. 2009.PubMed/NCBI
|
10.
|
Yao G: Entecavir is a potent anti-HBV drug
superior to lamivudine: experience from clinical trials in China. J
Antimicrob Chemother. 60:201–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Colonno RJ, Rose R, Baldick CJ, et al:
Entecavir resistance is rare in nucleoside naïve patients with
hepatitis B. Hepatology. 44:1656–1665. 2006.
|
12.
|
Wong VW, Wong GL, Yiu KK, et al: Entecavir
treatment in patients with severe acute exacerbation of chronic
hepatitis B. J Hepatol. 54:236–242. 2011. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Tsang SW, Chan HL, Leung NW, Chau TN, Lai
ST, Chan FK and Sung JJ: Lamivudine treatment for fulminant hepatic
failure due to acute exacerbation of chronic hepatitis B infection.
Aliment Pharmacol Ther. 15:1737–1744. 2001. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Sarin SK, Kumar A, Almeida JA, et al:
Acute-on-chronic liver failure: consensus recommendations of the
Asian Pacific Association for the study of the liver (APASL).
Hepatol Int. 3:269–282. 2009. View Article : Google Scholar
|
15.
|
Chan HL, Tsang SW, Hui Y, Leung NW, Chan
FK and Sung JJ: The role of lamivudine and predictors of mortality
in severe flare-up of chronic hepatitis B with jaundice. J Viral
Hepat. 9:424–428. 2002. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Tsubota A, Arase Y, Suzuki Y, et al:
Lamivudine monotherapy for spontaneous severe acute exacerbation of
chronic hepatitis B. J Gastroenterol Hepatol. 20:426–432. 2005.
View Article : Google Scholar : PubMed/NCBI
|
17.
|
Chien RN, Lin CH and Liaw YF: The effect
of lamivudine therapy in hepatic decompensation during acute
exacerbation of chronic hepatitis B. J Hepatol. 38:322–327. 2003.
View Article : Google Scholar : PubMed/NCBI
|
18.
|
Thabut D, Ratziu V, Bernard-Chabert B,
Poynard T, Benhamou Y and Thibault V: Unsuccessful rescue therapy
with adefovir dipivoxil for lamivudine resistant HBV in a patient
with liver failure. Gut. 52:6142003. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Wiegand J, Tischendorf JJ, Nashan B, et
al: Severe exacerbation of chronic hepatitis B after emergence of
lamivudine resistance in a cirrhotic patient: immediate switch to
adefovir dipivoxil appears to be indicated. Z Gastroenterol.
42:15–18. 2004. View Article : Google Scholar
|